Cargando…

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

SIMPLE SUMMARY: The EZH2-targeted drugs have demonstrated notable therapeutic effects in EZH2 mutant B-cell lymphoma patients. In this study, we demonstrated that the combination of EZH2 inhibitor SHR2554 and HDAC inhibitor HBI8000 exert synergistic anti-proliferative activity in both EZH2 wide-type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xing, Wang, Dedao, Ding, Ning, Mi, Lan, Yu, Hui, Wu, Meng, Feng, Feier, Hu, Luni, Zhang, Yime, Zhong, Chao, Ye, Yingying, Li, Jiao, Fang, Wei, Shi, Yunfei, Deng, Lijuan, Ying, Zhitao, Song, Yuqin, Zhu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428225/ https://www.ncbi.nlm.nih.gov/pubmed/34503063 http://dx.doi.org/10.3390/cancers13174249

Ejemplares similares

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia
por: Gu, Siyu, et al.
Publicado: (2023)

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
por: Que, Yi, et al.
Publicado: (2021)

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial
por: Deng, Kunhong, et al.
Publicado: (2022)

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
por: Coulter, Jonathan B., et al.
Publicado: (2023)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation
por: Li, Yongpan, et al.
Publicado: (2022)

Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
por: Cea, Michele, et al.
Publicado: (2011)

Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
por: Zuco, Valentina, et al.
Publicado: (2011)

Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl-2 pathway
por: Zhang, Hongwei, et al.
Publicado: (2021)

2554. Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine
por: Tasker, Sybil, et al.
Publicado: (2018)

A possible link to uracil DNA glycosylase in the synergistic action of HDAC inhibitors and thymidylate synthase inhibitors
por: Showler, Meredith S., et al.
Publicado: (2020)

Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
por: Hontecillas-Prieto, Lourdes, et al.
Publicado: (2020)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

The remarkable gymnastics of ORC
por: Stillman, Bruce
Publicado: (2022)

HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo
por: Huang, Hongbiao, et al.
Publicado: (2012)

2554. A Standardized Medicine Resident Curriculum: Content Survey for an Infectious Diseases Rotation
por: Enriquez, Matthew, et al.
Publicado: (2019)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
por: Yu, Hui, et al.
Publicado: (2021)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

SMAC Mimetics Synergistically Cooperate with HDAC Inhibitors Enhancing TNF-α Autocrine Signaling
por: Shibuya, Yusuke, et al.
Publicado: (2023)

Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN
por: Zhang, Guanhua, et al.
Publicado: (2017)

Management and clinical outcomes of follicular lymphoma across continuous lines of treatments: a retrospective analysis in China
por: Liu, Jiaxin, et al.
Publicado: (2023)

Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells
por: Grinshtein, Natalie, et al.
Publicado: (2016)

2554. What’s Weight Got to Do with It? Prospective Pharmacokinetic/Pharmacodynamic Evaluation of Fixed-Dose Daptomycin
por: Olney, Katie B, et al.
Publicado: (2023)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy
por: He, Yanjuan, et al.
Publicado: (2021)

The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
por: Wang, Yukun, et al.
Publicado: (2021)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin
por: Sun, Jun, et al.
Publicado: (2019)

The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis
por: Wang, Tsz Ki, et al.
Publicado: (2023)

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
por: Jiang, Xuejie, et al.
Publicado: (2021)

FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling
por: Yang, Yiqi, et al.
Publicado: (2023)

Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression
por: Chen, Cai-Ping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gsqp1e9f8024s9ato19d8ped9t